Goldman Sachs analyst David Roman downgraded Zimmer Biomet (ZBH) to Sell from Neutral with a price target of $93, down from $97. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. While the shares underperformed in 2025 on top-line growth deceleration and downside variance to quarterly organic growth estimates, Goldman does not expect an improvement in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside
- Zimmer Biomet downgraded to Market Perform from Outperform at Raymond James
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 28